Stabilize CIED placement
May help reduce CIED infection
Designed to hold a pacemaker
pulse generator or defibrillator to
create a stable environment when
implanted in the body.1, 2
Reduces chance of device migration,
erosion, or Twiddler Syndrome.1, 2
Synergistic combination of
minocycline and rifampin shown
to reduce infection in other medical
devices in multiple, randomized
controlled trials. 3-7
t; Elutes locally into the tissue for a
minimum of 7 days: site-specific,
adjunctive antibacterial protection. 8
Bioabsorbable mesh fully absorbs
into the body in 9 weeks.1
t; Requires no adjustment to standard
surgical techniques during
replacement or revision procedures.
t; After absorption, no foreign body
nidus for infection.
Multiple studies support clinical
t; Patients at high risk for CIED
infection implanted with the T YRX
Antibacterial Envelope had 70% to
90% fewer infections compared to
patients without it. *, 9 - 12
Significantly reduces costs of
infection in CIED implants.
t; Your facility can potentially reduce
costs by as much as $50,000 for
every 100 T YRX Envelopes used with
your high-risk CIED patients.*, 11-14
The TYRX Absorbable Antibacterial Envelope is NOT indicated for use in patients who have an allergy or history of allergies to tetracyclines, rifampin, or resorbable sutures.
The T YRX Absorbable Antibacterial Envelope is also NO T indicated for use in patients with contaminated or infected wounds, or Systemic Lupus Erythematosus (SLE). The use
of this product in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be considered carefully, because
minocycline and rifampin can cause additional stress on the hepatic and renal systems. Patients who receive the TYRX Absorbable Antibacterial Envelope and who are also
taking methoxyflurane should be monitored carefully for signs of renal toxicity.
*Studies performed utilizing the T YRX™ Antibacterial Envelope.
For more information visit T YRX.com & HeartDeviceInfection.com. Copyright ©2015. Medtronic T YRX, Inc.
1. Huntingdon Life Sciences Study TR-2011-054. 2. Hirsh J. EP Lab Digest, July 2012; 12( 7). 3. Leon C et al. Intensive Care Med. 2004; 30( 10):1891-1899. 4. Zambramski
JM et al. J Neurosurg. 2003;98( 4):725-730. 5. Chatzinikolaou I et al. Am J Med. 2003;115( 5):352-357. 6. Raad I et al. Ann Intern Med. 1997;128( 4):267-274. 7. Hanna
H et al. J Clin Oncol. 2004; 22(15):3163-3171. 8. TYRX Absorbable Antibacterial Envelope Instructions for Use. 9. Bloom HL et al. Pacing Clin Electrophysiol. 2011;
34( 2):133-142. 10. Henrikson CA, Citadel & Centurion Studies. Poster presentation at European Heart Rhythm Association (EHRA), Cardiostim 2014. 11. Kolek MJ et al. Pacing Clin
Electrophysiol. 2013; 36( 3):354-361. 12. Mittal S et al. Heart Rhythm. 2014; 11( 4):595-601. 13. Centers for Medicare & Medicaid Services, U. S. Department of Health and Human Services
Inpatient Prospective Payment System (IPPS) Final Rule F Y13. 14. Data on file, 090714-1.